Insulin Infusion Protocol for Severe Hypertriglyceridemia
For severe hypertriglyceridemia (triglycerides ≥1000 mg/dL), initiate continuous intravenous insulin infusion at 0.05-0.1 units/kg/hour with concurrent dextrose infusion to prevent hypoglycemia, targeting triglyceride reduction to <500 mg/dL.
Initial Assessment and Preparation
Before starting insulin infusion:
- Establish adequate renal function (urine output >0.5 mL/kg/h) 1
- Check baseline potassium - do not start insulin if K+ <3.3 mmol/L; replete first 2, 1
- Measure baseline glucose and triglyceride levels
- Identify and address secondary causes: uncontrolled diabetes, alcohol use, medications (estrogens, thiazides, beta-blockers, atypical antipsychotics, corticosteroids), hypothyroidism 3, 4
Insulin Infusion Dosing Protocol
Starting Dose
- Initial rate: 0.05-0.1 units/kg/hour 5, 6, 7
- Use regular insulin (short-acting) for IV infusion 2, 8
- Prepare at concentrations of 0.1-1 unit/mL in 0.9% sodium chloride 8
Dose Stratification by Patient Type
- Patients WITHOUT diabetes: Start at 0.05-0.075 units/kg/hour (lower risk of hypoglycemia) 9
- Patients WITH diabetes: May tolerate 0.075-0.1 units/kg/hour 5, 9
- Insulin-resistant patients (obesity, corticosteroid use): Consider higher end of dosing range 10
Critical Pitfall
Do NOT exceed 0.1 units/kg/hour - higher rates significantly increase hypoglycemia risk without improving efficacy 9. Patients without diabetes are particularly vulnerable to hypoglycemia and achieve target triglyceride levels faster than those with diabetes 9.
Concurrent Dextrose Administration
Mandatory dextrose infusion to prevent hypoglycemia:
- Start dextrose 5-10% infusion concurrently with insulin 6, 11
- Adjust dextrose rate to maintain blood glucose 100-180 mg/dL 12, 13
- This allows continued insulin infusion for triglyceride lowering while preventing hypoglycemia
Monitoring Requirements
Glucose Monitoring
- Every 1 hour or continuous glucose monitoring during insulin infusion 12, 13
- Use arterial or venous samples (not finger-stick) for accuracy in critically ill patients 13
- Target glucose: 100-180 mg/dL 12, 13
Triglyceride Monitoring
Electrolyte Monitoring
- Potassium every 2-4 hours - insulin drives K+ intracellularly 2, 1
- Maintain K+ between 4-5 mmol/L 2, 1
- Add potassium to IV fluids as needed (mix of KCl and KPO4) 2
- Monitor phosphate if patient develops muscle weakness or respiratory compromise 2
Expected Timeline to Resolution
Based on the largest case series 7 and protocol studies 6, 11:
- Triglycerides <1000 mg/dL: ~27-45 hours (1-2 days)
- Triglycerides <500 mg/dL: ~50-75 hours (2-3 days)
- Total infusion duration: median 2.5-3 days
Patients without diabetes achieve targets faster (27.6 hours vs 56.8 hours for those with diabetes) 11.
Hypoglycemia Management
If blood glucose <70 mg/dL 14:
- Give 15-20g IV dextrose immediately
- Do NOT stop insulin infusion - this will cause triglyceride rebound
- Increase dextrose infusion rate instead
- Recheck glucose in 15 minutes
- Document and review protocol to prevent recurrence 14
Hypoglycemia occurs in 7-27% of patients depending on protocol adherence 5, 6, 9.
Transition to Subcutaneous Therapy
When triglycerides <500 mg/dL and patient stable:
- Start fibrate therapy (first-line for severe hypertriglyceridemia) 4
- Add omega-3 fatty acids 3, 4
- Initiate subcutaneous basal insulin 2 hours before stopping IV insulin 14, 1
- Calculate subcutaneous dose based on last 6-8 hours of stable IV insulin rate 14
- Continue IV insulin for 1-2 hours overlap to prevent rebound hyperglycemia 2, 14
Adjunctive Measures
- Very low-fat diet (<10-15% of calories from fat) 3, 4
- Avoid refined carbohydrates and alcohol completely 3, 4
- Optimize glycemic control if diabetic 3
- Consider plasmapheresis only if triglycerides remain >1000 mg/dL despite 24-48 hours of insulin therapy 6
Quality Metrics
Track these outcomes for protocol improvement 13:
- Hypoglycemia rate (target <10%)
- Time to triglycerides <500 mg/dL
- Hypokalemia incidence (occurs in ~29% of patients) 5
This protocol provides standardized, evidence-based management that reduces triglycerides safely while minimizing the 7-27% hypoglycemia risk seen with non-standardized approaches 6, 11.